A study to investigate the effect of rosuvastatin (CRESTOR®) on high density lipoprotein kinetics in patients with the metabolic syndrome

Study identifier:4522AS/0004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, double-blind, placebo controlled, crossover dose-ranging study to investigate the effect of rosuvastatin (CRESTOR®) on high density lipoprotein kinetics in patients with the metabolic syndrome

Medical condition

Metabolic Syndrome

Phase

Phase 3

Healthy volunteers

Yes

Study drug

Rosuvastatin

Sex

Male

Actual Enrollment

15

Study type

Interventional

Age

30 Years - 70 Years

Date

Study Start Date: 01 Apr 2004
Primary Completion Date: -
Study Completion Date: 01 May 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria